CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis

Research output: Contribution to journalLetterpeer-review

4 Scopus citations
Original languageEnglish
Pages (from-to)e4-e5
JournalBritish Journal of Haematology
Volume200
Issue number1
DOIs
StatePublished - Jan 2023

Keywords

  • B-cell
  • CAR-T
  • CD19
  • chimaeric antigen receptor
  • diffuse large cell
  • lymphoma
  • lymphoma
  • meta-analysis
  • refractory relapse

Cite this